



Professor Sir Peter Horby, Professor Sir Martin Landray
RECOVERY trial Co-chairs
Nuffield Department of Population Health
Oxford

22nd March 2024

Dear Peter and Martin

RECOVERY trial DMC report

Today we reviewed the RECOVERY trial safety and efficacy data that were available for patients randomised by 18th March 2024.

For the interventions for COVID still in active recruitment, the numbers of individuals included in the comparison of each agent with its control were respectively: high dose steroids (only in patients requiring ventilation) (477) and sotrovimab (1,722).

For the interventions for influenza, the numbers of individuals included in the comparison of each agent with its control were respectively: Baloxavir marboxil (250), Oseltamavir (47) and Dexamethasone (72).

The dataset included 4 women who were pregnant at entry and 7 children.

In the light of the available trial data and all relevant external information, we saw no cogent reason to modify the protocol or intake to the study.

The DMC will next meet to review the safety and efficacy data for all treatments in about 6 months time (or sooner if there is a marked increase in recruitment).

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE
Chairman RECOVERY trial DMC
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
t: +44 (0)131 465 9602 / w: www.ccbs.ed.ac.uk / e: Peter.sandercock@ed.ac.uk